Tofacitinib is a new drug made by Pfizer seeking approval from the FDA for the treatment of rheumatoid arthritis. It is a novel approach since tofacitinib is taken twice daily by mouth compared to injectable biologics. It works uniquely by blocking janus kinase (JAK) enzymes inside cells. New studies, paid for by Pfizer, were published in the New England Journal of Medicine showing a reduced number of swollen and painful joints compared to placebo. Common side effects include upper respiratory tract infection, headache, increased LDL and diarrhea. Some serious adverse effects include reduced white blood cell count, as well as a weakened immune system. Are you excited about this new convenient route of administration? Do you think this drug will help with patient compliance?